"The thematic thesis presented: psychedelic biotechnology firms represent a high-upside sector supported by regulatory tailwinds and Big Pharma validation."

"The speaker argued big pharma M&A and regulatory momentum validate psychedelic medicine as a structural threat to traditional antidepressants."